Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

88,329 results
MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 1
1951 3
1952 3
1953 5
1954 6
1955 5
1956 6
1957 2
1958 8
1959 28
1960 34
1961 31
1962 27
1963 2
1964 6
1965 53
1966 115
1967 166
1968 232
1969 242
1970 281
1971 293
1972 284
1973 260
1974 328
1975 304
1976 275
1977 371
1978 359
1979 352
1980 412
1981 455
1982 476
1983 560
1984 619
1985 693
1986 681
1987 807
1988 852
1989 1028
1990 1019
1991 1041
1992 1091
1993 1170
1994 1283
1995 1316
1996 1298
1997 1365
1998 1439
1999 1508
2000 1666
2001 1903
2002 2072
2003 2153
2004 2381
2005 2605
2006 2748
2007 3130
2008 3413
2009 3594
2010 4184
2011 4442
2012 4879
2013 5117
2014 5709
2015 5915
2016 5426
2017 5356
2018 4973
2019 1627
Text availability
Article attribute
Article type
Publication date

Search Results

88,329 results
Results by year
Filters applied: . Clear all
Page 1
Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.
Coates AS, et al. Ann Oncol 2015. PMID 25939896 Free PMC article.
For the treatment of HER2-positive disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simplified regimen comprising paclitaxel and trastuzumab without anthracycline as adjuvant therapy. ...
For the treatment of HER2-positive disease in patients with node-negative cancers up to 1 cm, the Panel endorsed a simplified regimen comprising paclitaxel and trastuzumab without anthracycline as adjuvant therapy. ...
Perioperative Management of Hilar Cholangiocarcinoma
Poruk KE, et al. J Gastrointest Surg 2015 - Review. PMID 26022776 Free PMC article.
As a result of recent efforts, new methods of management have been identified for these patients, including preoperative portal vein embolism and biliary drainage, neoadjuvant chemotherapy with subsequent transplantation, and chemoradiation therapy. CONCLUSION: Current management of hilar cholangiocarcinoma depends on extent of the tumor at presentation and includes surgical resection, liver transplantation, portal vein embolization, and chemoradiation therapy. ...
As a result of recent efforts, new methods of management have been identified for these patients, including preoperative portal vein embolism and biliary drainage, neoadjuvant chemotherapy with subsequent transplantation, and chemoradiation therapy. CONCLUSION: Current management of hilar cho …
Therapy of adenocarcinoma of unknown primary: are we making progress?
Greco FA. J Natl Compr Canc Netw 2008 - Review. PMID 19176201
Therapy for patients with unknown primary carcinoma is evolving and requires a detailed understanding of the various clinicopathologic subsets with more favorable prognoses. ...Approximately 60% of the patients with unknown primary adenocarcinoma have clinically occult primary sites of colon/rectum, lung, and pancreas. ...
Therapy for patients with unknown primary carcinoma is evolving and requires a detailed understanding of the various clinicopathologic subsets with more favorable prognoses. ...Approximately 60% of the patients with unknown primary adenocarcinoma have clinically occult primary sites of
Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis.
Saeed H, et al. J Surg Oncol 2016. PMID 27238300
BACKGROUND: Long-term results of the ESPAC-3 trial suggest that while completing adjuvant therapy (AT) is necessary after resection of pancreatic ductal adenocarcinoma (PDAC), early initiation (within 8 weeks) may not be associated with improved overall survival (OS). ...
BACKGROUND: Long-term results of the ESPAC-3 trial suggest that while completing adjuvant therapy (AT) is necessary after resection of pancreatic ductal adenocarcinoma (PDAC), early initiation (within 8 weeks) may not be associated with improved overall survival (OS). ...
Initiation of adjuvant therapy following surgical resection of pancreatic ductal adenocarcinoma (PDAC): Are patients from rural, remote areas disadvantaged?
Bertens KA, et al. J Surg Oncol 2018. PMID 29761510
BACKGROUND AND OBJECTIVES: Although race and socioeconomic status have been shown to affect outcomes in pancreatic ductal adenocarcinoma (PDAC), the impact of rural residence on the delivery of adjuvant therapy (AT) has not been studied. ...
BACKGROUND AND OBJECTIVES: Although race and socioeconomic status have been shown to affect outcomes in pancreatic ductal adenocarcinoma (PDAC), the impact of rural residence on the delivery of adjuvant therapy (AT) has not been studied. ...
Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma.
Álvarez R, et al. Clin Transl Oncol 2017 - Review. PMID 28612203
Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic ductal adenocarcinoma, allowing the early application of systemic therapies, has also increased. ...
Nowadays and given the improvement in response rate with the new schemes of treatment with chemotherapy, the interest in neoadjuvant treatment for pancreatic ductal adenocarcinoma, allowing the early application of systemic therapies, has also increased. ...
The Role of Radiotherapy in Extramammary Paget Disease: A Systematic Review
Tagliaferri L, et al. Int J Gynecol Cancer 2018. PMID 29538255
Surgery is the recommended therapy for resectable and localized disease, but several other local treatments have been reported such as radiotherapy (RT). ...
Surgery is the recommended therapy for resectable and localized disease, but several other local treatments have been reported such as radiotherapy (RT). ...
88,329 results
Jump to page
Feedback